Avanos Medical (NYSE:AVNS) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Avanos Medical (NYSE:AVNS) from a buy rating to a hold rating in a research report released on Saturday.

Several other brokerages also recently issued reports on AVNS. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce”.

Avanos Medical Stock Up 2.1%

AVNS stock opened at $13.71 on Friday. The stock has a market capitalization of $637.37 million, a P/E ratio of -8.67 and a beta of 1.07. The company has a current ratio of 2.15, a quick ratio of 1.26 and a debt-to-equity ratio of 0.12. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $15.68. The firm has a 50-day moving average price of $13.49 and a 200-day moving average price of $12.27.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. The company had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The firm’s revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, equities research analysts anticipate that Avanos Medical will post 1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AVNS. EverSource Wealth Advisors LLC boosted its position in Avanos Medical by 132.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after acquiring an additional 1,423 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Avanos Medical by 49.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares in the last quarter. Wexford Capital LP acquired a new position in shares of Avanos Medical in the 3rd quarter valued at about $70,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after purchasing an additional 5,083 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.